Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$124.11-2.60%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · HAE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 11.0% |
| Our one-year growth estimate | diamond | 7.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
HAE — officer change
Dated 2026-05-01
Director — Charles J. Dockendorff: Mr. Dockendorff will not stand for re-election at the Company’s 2026 Annual Meeting.
Why it matters: Tariffs, freight, and staff costs have pressured margins. A lasting rise in these costs could make the margin goal harder to reach.
Worry ifAdjusted gross margin stays below 60%, while freight or tariff costs rise again in a later report.
Less concerning ifAdjusted gross margin reaches 60% or more, and management reports less pressure from freight and tariffs.
Why it matters: The next report can test whether Plasma share gains and MedSurg growth continue. Q1 organic growth was 5.9%.
Watch forThe November 5 report shows organic growth of at least 5.9%. Both Apheresis and MedSurg grow from last year.
Also watch forThe November 5 report shows organic growth below 4%, or either business unit falls from last year.
Why it matters: The company targets about 80% cash conversion. Q1 cash flow rose, but timing of customer payments helped drive the increase.
Watch forFull-year free cash flow divided by adjusted net income is about 80% or higher.
Also watch forFull-year free cash flow conversion falls well below 80%, or cash flow drops as customer payments slow.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$82 on $10,000 · ±0.8% | How much price usually moves either way. |
| Bad day | $307 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,006 loss on $10,000 · 40.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.